About Signia Therapeutics innovative technology

About Signia Therapeutics innovative technology

Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company’s proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication against one or several human respiratory viruses that could be evaluated in clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.